The investigation follows a significant market correction on February 13, 2026, when Disc Medicine shares plummeted 22%. That drop occurred after the U.S. Food and Drug Administration issued a Complete Response Letter regarding the company’s bitopertin program. Regulators indicated they could not approve the new drug application, citing unresolved uncertainties that required further evidentiary support.

Rosen Law Firm, which is spearheading the potential litigation, is soliciting participants who purchased company securities. The firm notes that participants would not face out-of-pocket costs due to a contingency fee arrangement. Shareholders interested in participating can contact attorney Phillip Kim via the firm's legal portal or through direct communication channels. The firm emphasizes its history in securities litigation, citing past rankings by ISS Securities Class Action Services and recoveries totaling billions of dollars, to distinguish its practice from other entities issuing similar investor notices.